News for Bright Minds Biosciences Inc. (DRUG.CN)

VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) ( DRUG) (”œBright Minds” or the ”œCompany”), a

”“ Dennis Dlugos, MD, MSCE; Jacqueline French, MD; Terrence O'Brien, MD; Jo Sourbron, MD, PhD, MPharm; and Joseph Sullivan, MD, bring decades of experience in

VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ('Bright Minds” or the 'Company”) announces that further to its news release of October 18, 2024, the Company has closed a non-brokered private placement of 1,612,902 common shares in the capital of the Company ('Shares”) at a price of USD$21.70 per Share for aggregate gross proceeds of USD$35,000,000 (the 'Offering”).

VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) — Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“

**media[440460]**

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO TH…

Bright Minds is Unaware of Any Material Changes

Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th

Bright Minds Announces Closing of Non-Brokered Private Placement Fully Subscribed by Management Vancouver, British Columbia, December 22, 2023 - Bright Minds...

single dose Reached the planned top dose of 180 mg/70 kg, which approached preclinical exposure limits Well tolerated with...

— Presentation entitled “BMB-101: A selective 5-HT

VANCOUVER, British Columbia, Feb. 08, 2023 (GLOBE NEWSWIRE) — Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“